This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.
Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure information is available at the beginning of the video presentation.
- Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC ( Download)
- Improving Survival and Cure Rates in Resectable NSCLC With Perioperative Immunotherapy ( Download)
- Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLC ( Download)
- How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLC ( Download)
- Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC ( Download)
- Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC ( Download)
- IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLC ( Download)
- Advances in Immunotherapy & Resectable Non-Small Cell Lung Cancer ( Download)
- Perioperative Immunotherapy for Resectable NSCLC: Evaluating Approved and Emerging Approaches ( Download)
- Perioperative therapies in NSCLC ( Download)
- Elevating Care in Resectable Stage I-III NSCLC ( Download)
- Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines ( Download)
- 8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC ( Download)
- Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC ( Download)
- Drs. Altorki & Spicer discuss #NSCLC #Immunotherapy at #ThoracicSummit2022 - https://bit.ly/3BXcsbV ( Download)
